Oasmia presents Phase III-results in Denmark
Oasmia presents Phase III results for Paclical® Vet in Copenhagen
The company Oasmia Pharmaceutical will present the first results from a Phase III-study with the drug candidate Paclical® Vet at a veterinary congress in Copenhagen. The top veterinary oncologists in the USA and Europe will attend the congress.
Oasmia has performed a Phase III-study with the drug candidate Paclical® Vet on dogs with mastocytoma grade II-III during 2007-2008. The company will present the first results at the congress ESVONC and VCS joint meeting in Copenhagen during February 28 to March 1 2008. The company is main sponsor for the congress.
ESVONC (European Society of Veterinary Oncology) is an association of the most prominent veterinary oncologists in Europe. VCS (Veterinary Cancer Society) is the ESVONC's American counterpart. The congress is the first that these two organizations are holding together.
- It is incredibly exciting that Oasmia has chosen to present Phase III-data at the first world congress for cancer in animals concerning the first cytostatic planned to be registered for veterinary use, says Annemarie T. Kristensen, professor of oncology, Institute for Small Animal Diseases, Copenhagen University.
- It is very important that we can present the first Phase III-results at this key event and we are delighted to support this congress as one of the main sponsors, says Oasmia CEO Julian Aleksov in a comment.
The participation and presentation will open many new collaboration opportunities for Oasmia's veterinary medicine operations as the drug candidate now is a lot closer to registration in Europe and the USA.
The press release is available in PDF-format here.
